These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26398574)

  • 1. Review of Properties and Analytical Methods for the Determination of Norfloxacin.
    Chierentin L; Salgado HR
    Crit Rev Anal Chem; 2016; 46(1):22-39. PubMed ID: 26398574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of norfloxacin by 1H NMR and HPLC.
    Frackowiak A; Kokot ZJ
    Acta Pol Pharm; 2012; 69(4):597-601. PubMed ID: 22876600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria.
    Moros M; Coll R; Esteve M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373
    [No Abstract]   [Full Text] [Related]  

  • 4. [Norfloxacin: a broad-spectrum quinolone for superficial eye infections].
    Grosset J
    Pathol Biol (Paris); 1990 Sep; 38(7):735-41. PubMed ID: 2235090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
    Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
    Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
    Chemioterapia; 1987 Feb; 6(1):17-22. PubMed ID: 3470153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the fluoroquinolone antibiotics.
    Just PM
    Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis.
    Ramos JM; Vidal I; Bellot P; Gómez-Hurtado I; Zapater P; Such J
    Gut; 2016 Jan; 65(1):182-3. PubMed ID: 25832107
    [No Abstract]   [Full Text] [Related]  

  • 9. [In vitro activity of norfloxacin against gram-positive and gram-negative organisms from recent clinical isolates].
    Mancini C; Brenciaglia MI; Ghezzi MC; Giordano A; Nazzari C; Cipriani P
    Boll Ist Sieroter Milan; 1985; 64(4):289-93. PubMed ID: 3935135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
    Drugs Exp Clin Res; 1987; 13(9):555-61. PubMed ID: 3480796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
    Husson MO; Izard D; Bryskier A; Leclerc H
    Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro evaluation of lomefloxacin].
    Dette GA; Knothe H
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and N-[(2-5-bromothiophen-2-yl)-2-oximinoethyl] derivatives of piperazinyl quinolones.
    Foroumadi A; Emami S; Mehni M; Moshafi MH; Shafiee A
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4536-9. PubMed ID: 16115766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial activity of norfloxacin against 1700 relatively resistant clinical isolates.
    Qadri SM; Lee G; Brodie L
    Drugs Exp Clin Res; 1989; 15(8):349-53. PubMed ID: 2598776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of resistance to fluoroquinolones among gram positive and gram negative clinical isolates.
    Nesar S; Shoaib MH; Rahim N; Rehman R
    Pak J Pharm Sci; 2012 Oct; 25(4):877-81. PubMed ID: 23010009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial effect of some essential oils administered alone or in combination with Norfloxacin.
    Rosato A; Vitali C; De Laurentis N; Armenise D; Antonietta Milillo M
    Phytomedicine; 2007 Nov; 14(11):727-32. PubMed ID: 17303397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria.
    Kerns RJ; Rybak MJ; Cheung CM
    Diagn Microbiol Infect Dis; 2006 Apr; 54(4):305-10. PubMed ID: 16466892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro comparative activity of norfloxacin in the comparison of pathogenic bacteria of the urinary tract].
    Carlone NA; Cuffini AM; Tullio V; Savoia D; Cavallo GP
    G Batteriol Virol Immunol; 1986; 79(1-6):85-97. PubMed ID: 3479370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.